ApoB-48 and apoB-100 differentially influence the expression of type-III hyperlipoproteinemia in APOE*2 mice

Journal of Lipid Research

Volumn 43, Issue 9, 2002, Pages 1520-1528

  Hinsdale, Myron E ^a   Sullivan, Patrick M ^a   Mezdour, Hafid ^a   Maeda, Nobuyo ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Lipoprotein remnants; Lipoproteins; Metabolism; Very low density lipoprotein

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN E2; CHOLESTEROL; CHYLOMICRON; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; VERY LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN B; APOLIPOPROTEIN E; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE LOCUS; HOMOZYGOSITY; HYPERLIPOPROTEINEMIA TYPE 3; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR BINDING; SPECIES DIFFERENCE; ANIMAL; BLOOD; GENETICS; METABOLISM; MOUSE MUTANT; POLYACRYLAMIDE GEL ELECTROPHORESIS; SECRETION; WESTERN BLOTTING;

ANIMALS; APOLIPOPROTEIN B-100; APOLIPOPROTEIN B-48; APOLIPOPROTEIN E2; APOLIPOPROTEINS B; APOLIPOPROTEINS E; BLOTTING, WESTERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HYPERLIPOPROTEINEMIA TYPE III; LIPOPROTEINS, VLDL; MALE; MICE; MICE, KNOCKOUT; PHENOTYPE; TRIGLYCERIDES;

EID: 0036740644     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M200103-JLR200     Document Type: Article

References (43)

1. Utermann, G., M. Hees, and A. Steinmetz. 1977. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature. 269: 604-607.
2. Mahley, R. W., and S. C. Rall, Jr. 1995. Type III hyperlipoproteinemia (Dysbetalipoproteinemia): The Role of Apolipoprotein E in Normal and Abnormal Metabolism. In The Molecular and Metabolic Bases of Inherited Disease. 7th edition. Volume 2. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle. McGraw-Hill, Inc., New York, New York. 1953-1980.
3. Mahley, R. W., Y. Huang, and S. C. Rall, Jr. 1999. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J. Lipid Res. 40: 1933-1949.
4. Davignon, J., J. S. Cohn, L. Mabile, and L. Bernier. 1999. Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin. Chim. Acta. 286: 115-143.
5. Sullivan, P. M., H. Mezdour, S. H. Quarfordt, and N. Maeda. 1998. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J. Clin. Invest. 102:130-135.
6. Knouff, C., M. E. Hinsdale, H. Mezdour, M. K. Altenburg, M. Watanabe, S. H. Quarfordt, P. M. Sullivan, and N. Maeda. 1999. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J. Clin. Invest. 103: 1579-1586.
7. Knouff, C., S. Malloy, J. Wilder, M. K. Altenburg, and N. Maeda. 2000. Doubling expression of the LDL receptor by truncation of the 3′ UTR sequence ameliorates type III hyperlipoproteinemia in mice expressing the Human ApoE2 isoform. J. Biol. Chem. 276: 3856-3862.
8. Powell, L. M., S. C. Wallis, R. J. Pease, Y. H. Edwards, T. J. Knott, and J. Scott. 1987. A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell. 50: 831-840.
9. Chen, S. H., G. Habib, C. Y. Yang, Z. W. Gu, B. R. Lee, S. A. Weng, S. R. Silberman, S. J. Cai, J. P. Deslypere, M. Rosseneu, A. M. Gotto Jr., W. H. Li, and L. Chan. 1987. Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science. 238: 363-366.
10. Oka, K., K. Kobayashi, M. Sullivan, J. Martinez, B. B. Teng, K. Ishimura-Oka, and L. Chan. 1997. Tissue-specific inhibition of apolipoprotein B mRNA editing in the liver by adenovirus-mediated transfer of a dominant negative mutant APOBEC-1 leads to increased low density lipoprotein in mice. J. Biol. Chem. 272: 1456-1460.
11. Higuchi, K., K. Kitagawa, K. Kogishi, and T. Takeda. 1992. Developmental and age-related changes in apolipoprotein B mRNA editing in mice. J. Lipid Res. 33: 1753-1764.
12. Morrison, J. R., C. Paszty, M. E. Stevens, S. D. Hughes, T. Forte, J. Scott, and E. M. Rubin. 1996. Apolipoprotein B RNA editing enzyme-deficient mice are viable despite alterations in lipoprotein metabolism. Proc. Natl. Acad. Sci. USA. 93: 7154-7159.
13. Warnick, G. R., J. Benderson, and J. J. Albers. 1982. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin. Chem. 28:1379-1388.
14. Sullivan, P. M., H. Mezdour, Y. Aratani, C. Knouff, J. Najib, R. L. Reddick, S. H. Quarfordt, and N. Maeda. 1997. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 272: 17972-17980.
15. van Dijk, K. W., B. J. van Vlijmen, H. B. van't Hof, A. van der Zee, S. Santamarina-Fojo, T. J. van Berkel, L. M. Havekes, and M. H. Hofker. 1999. In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE. J. Lipid Res. 40: 336-344.
16. Maugeais, C., U. J. Tietge, K. Tsukamoto, J. M. Glick, and D. J. Rader. 2000. Hepatic apolipoprotein E expression promotes very low density lipoprotein-apolipoprotein B production in vivo in mice. J. Lipid Res. 41: 1673-1679.
17. Li, X., F. Catalina, S. M. Grundy, and S. Patel. 1996. Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins. J. Lipid Res. 37: 210-220.
18. Wish L., J. Furth, and R. H. Storey. 1950. Direct determination of plasma, cell, and organ-blood volumes in normal and hypervolemic mice. Proc. Soc. Exp. Biol. Med. 74: 644-648.
19. Zhang, S. H., R. L. Reddick, J. A. Piedrahita, and N. Maeda. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258: 468-471.
20. Nakamuta, M., S. Taniguchi, B. Y. Ishida, K. Kobayashi, and L. Chan. 1998. Phenotype interaction of apobec-1 and CETP, LDLR, and apoE gene expression in mice: role of apoB mRNA editing in lipoprotein phenotype expression. Arterioscler. Thromb. Vasc. Biol. 18: 747-755.
21. Farese, R. V., Jr., M. M. Veniant, C. M. Cham, L. M. Flynn, V. Pierotti, J. F. Loring, M. Traber, S. Ruland, R. S. Stokowski, D. Huszar, and S. G. Young. 1996. Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. Proc. Natl. Acad. Sci. USA. 93: 6393-6398.
22. Ferrieres, J., C. F. Sing, M. Roy, J. Davignon, and S. Lussier-Cacan. 1994. Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia. Sex-specific effects. Arterioscler. Thromb. 14: 1553-1560.
23. Woollett, L. A., Y. Osono, J. Herz, and J. M. Dietschy. 1995. Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse. Proc. Natl. Acad. Sci. USA. 92: 12500-12504.
24. Davignon, J., R. E. Gregg, and C. F. Sing. 1988. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 8: 1-21.
25. Jong, M. C., V. E. Dahlmans, M. H. Hofker, and L. M. Havekes. 1997. Nascent very-low-density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner. Biochem. J. 328: 745-750.
26. Huang, Y., X. Q. Liu, S. C. Rall, Jr., and R. W. Mahley. 1998. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. J. Biol. Chem. 273: 17483-17490.
27. Huang, Y., X. Q. Lin, S. C. Rall, Jr., J. M. Taylor, A. von Eckardstein, G. Assmann, and R. W. Mahley. 1998. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J. Biol. Chem. 273: 26388-26393.
28. Huang, Y., Z. S. Ji, W.J. Brecht, S. C. Rall, Jr., J. M. Taylor, and R. W. Mahley. 1999. Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis. Arterioscler. Thromb. Vasc. Biol. 19: 2952-2959.
29. Kendrick, J. S., L. Chan, and J. A. Higgins. 2001. Superior role of apolipoprotein B48 over apolipoprotein B100 in chylomicron assembly and fat absorption: an investigation of apobec-1 knock-out and wild-type mice. Biochem. J. 356: 821-827.
30. Veniant, M. M., S. Withycombe, and S. G. Young. 2001. Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice. Arterioscler. Thromb. Vasc. Biol. 21: 1567-1570.
31. Veniant, M. M., M. A. Sullivan, S. K. Kim, P. Ambroziak, A. Chu, M. D. Wilson, M. K. Hellerstein, L. L. Rudel, R. L. Walzem, and S. G. Young. 2000. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. J. Clin. Invest. 106: 1501-1510.
32. Krul, E. S., M. Kinoshita, P. Talmud, S. E. Humphries, S. Turner, A. C. Goldberg, K. Cook, E. Boerwinkle, and G. Schonfeld. 1989. Two distinct truncated apolipoprotein B species in a kindred with hypobetalipoproteinemia. Arteriosclerosis. 9: 856-868.
33. Parhofer, K. G., P. H. Barrett, D. M. Bier, and G. Schonfeld. 1992. Lipoproteins containing the truncated apolipoprotein, Apo B-89, are cleared from human plasma more rapidly than Apo B-100containing lipoproteins in vivo. J. Clin. Invest. 89: 1931-1937.
34. Parhofer, K. G., A. Daugherty, M. Kinoshita, and G. Schonfeld. 1990. Enhanced clearance from plasma of low density lipoproteins containing a truncated apolipoprotein, apoB-89. J. Lipid Res. 31: 2001-2007.
35. Krul, E. S., K. G. Parhofer, P. H. Barrett, R. D. Wagner, and G. Schonfeld. 1992. ApoB-75, a truncation of apolipoprotein B associated with familial hypobetalipoproteinemia: genetic and kinetic studies. J. Lipid Res. 33: 1037-1050.
36. Homanics, G. E., T.J. Smith, S. H. Zhang, D. Lee, S, G. Young, and N. Maeda. 1993. Targeted modification of the apolipoprotein B gene results in hypobetalipoproteinemia and developmental abnormalities in mice. Proc. Natl. Acad. Sci. USA. 90: 2389-2393.
37. Toth, L. R., T. J. Smith, C. Jones, H. V. de Silva, O. Smithies, and N. Maeda. 1996. Two distinct apolipoprotein B alleles in mice generated by a single 'in-out' targeting. Gene. 178: 161-168.
38. Kim, E., C. M. Cham, M. M. Veniant, P. Ambroziak, and S. G. Young. 1998. Dual mechanisms for the low plasma levels of truncated apolipoprotein B proteins in familial hypobetalipoproteinemia. Analysis of a new mouse model with a nonsense mutation in the Apob gene. J. Clin. Invest. 101: 1468-1477.
39. Srivastava, R. A., L. Toth, N. Srivastava, M. E. Hinsdale, N. Maeda, A. B. Cefalu, M. Averna, and G. Schonfeld. 1999. Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB. Mol. Cell. Biochem. 202: 37-46.
40. Boren, J., I. Lee, W. Zhu, K. Arnold, S. Taylor, and T. L. Innerarity. 1998. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. J. Clin. Invest. 101: 1084-1093.
41. McConathy, W. J., and C. S. Wang. 1989. Inhibition of lipoprotein lipase by the receptor-binding domain of apolipoprotein E. FEBS Lett. 251: 250-252.
42. Boren, J., U. Ekstrom, B. Agren, P. Nilsson-Ehle, and T. L. Innerarity. 2001. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J. Biol. Chem. 276: 9214-9218.
43. Chappell, D. A., and J. D. Medh. 1998. Receptor-mediated mechanisms of lipoprotein remnant catabolism. Prog. Lipid Res. 37: 393-422.